Latest Research And Development News

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

BPH Global is expanding its seaweed biomass research to develop renewable biofuels like biohydrogen and biocrude, aiming to carve out a sustainable alternative to fossil fuels in energy and transport sectors.

Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.

Tetratherix Limited launches a new precision medicine franchise leveraging its Tetramatrix™ platform, securing a decade-long exclusive partnership with US health group Superpower Health Inc. This deal promises immediate revenue and complements ongoing FDA milestones.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.

Elixir Energy has completed drilling the Lorelle-3H well in Queensland’s Taroom Trough, achieving over 1,000 metres of high-quality net gas-condensate pay and setting a new benchmark for lateral drilling in the basin. A multi-stage fracture stimulation and production test is planned for Q2 2026, potentially paving the way for Elixir’s first reserves booking.

Acrux Limited has secured a $0.55 million advance on its FY26 R&D Tax Incentive, providing crucial funding to accelerate development of its Hormone Replacement Therapy following FDA regulatory confirmation.

ABx Group has secured partnerships in two major Australian Government R&D initiatives aimed at advancing rare earths refining and exploration technologies, accelerating development of its ionic clay rare earth project in Tasmania.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Janus Electric has locked in a $2.75 million R&D finance facility, strengthening its cash position to push forward with its zero-emission transport innovations. This strategic funding avoids shareholder dilution while supporting ongoing technology development.

Island Pharmaceuticals has entered a pivotal research agreement with USAMRIID and the Geneva Foundation to accelerate FDA approval of Galidesivir for Marburg Virus Disease, leveraging top-tier US biodefense expertise.